Wu Xiaobin 4

What Happened

• Wu Xiaobin, President and Chief Operating Officer of BeOne Medicines Ltd. (ONC), received two performance-based awards on 2026-03-06 totaling 247,546 ordinary shares (168,922 + 78,624). Each award was reported as an acquisition (Code A) at a grant price of $0.00; there was no cash paid for these grants.

Key Details

• Transaction date(s) and price(s): 2026-03-06; 168,922 shares @ $0.00 (F1) and 78,624 shares @ $0.00 (F2).
• Total awarded: 247,546 ordinary shares (aggregate).
• Vesting: The 168,922 PSU award vests in 2027 (F1); the 78,624 PSU award vests in 2028 (F2). Vesting is conditioned on continued service; unvested awards may accelerate on certain termination events.
• ADS note: Each American Depositary Share represents 13 ordinary shares (F3) — the filing reports ordinary-share equivalents.
• Shares owned after transaction: Not disclosed in this Form 4.
• Filing timeliness: Report filed 2026-03-10 for transactions on 2026-03-06; this was filed within the Form 4 reporting window (timely).

Context

• These were performance share unit grants (awards), not market purchases or sales. PSUs convert to ordinary shares only if vesting and performance/service conditions are met, so they are a forward-looking compensation award rather than an immediate change in insider cash exposure.
• No options were exercised, no shares were sold, and no 10b5-1, tax-withholding, or gift codes were reported in this filing.